Petridis A, et al. - Researchers herein, evaluated the relationship of body mass index (BMI) and waist circumference (WC) with the severity of moderate-to-severe plaque psoriasis and determined the potential patient characteristics associated with response attainment. Additionally, they gauged the effect of infliximab on the health-related quality of life (HRQoL) of patients among the individuals treated with infliximab in Greece. Disease activity was noted to be reduced. As per the outcomes, the quality of life of moderate-to-severe psoriasis patients improved due to infliximab, through one year of treatment, independent of their body mass index (BMI) and waist circumference (WC).